Trial · NCT00559104

Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

NCT00559104, Phase 2, Completed, City of Hope Medical Center; results first posted 2015-08-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma. Trials, record NCT00559104. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00559104

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
NCT number: NCT00559104
Status: Completed
Phases: Phase 2
Enrollment: 60 participants, actual
Lead sponsor: City of Hope Medical Center
Conditions: Lymphoma
Interventions: carmustine, cyclophosphamide, etoposide, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, G-CSF
First posted: 2007-11-16
Last updated: 2015-08-11
Results first posted: 2015-08-11

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression	Assessed at date of progression post-transplant	Event will be recorded if it occurs any time post-transplant, until date of death, last recorded contact, or end-of-study; whichever comes first. Below is reported Progression-free Survival: event is relapse or progression, or death.
Primary	Mortality	Assessed at date of death post-transplant	Event will be recorded if it occurs any time from the date of transplant until the end-of-study date, or the date of last contact, whichever comes first.
Secondary	Short-term and Long-term Treatment-related Toxicities	Any time after transplant	Patient may be assessed for toxicities any time after transplant, up to death, last contact date, or end-of-study date.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression	Assessed at date of progression post-transplant	per protocol	participants	NUMBER
PRIMARY	Mortality	Assessed at date of death post-transplant	per protocol	participants	NUMBER
SECONDARY	Short-term and Long-term Treatment-related Toxicities	Any time after transplant	per protocol	participants	NUMBER

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Progression	Irradiation in Conditioning	22	participants
Progression	Carmustine in Conditioning	1	participants
Mortality	Irradiation in Conditioning	19	participants
Mortality	Carmustine in Conditioning	1	participants
Short-term and Long-term Treatment-related Toxicities	Irradiation in Conditioning	39	participants
Short-term and Long-term Treatment-related Toxicities	Carmustine in Conditioning	1	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	TBI-based Conditioning	55
Overall Study	STARTED	nonTBI-based Conditioning	5
Overall Study	COMPLETED	TBI-based Conditioning	46
Overall Study	COMPLETED	nonTBI-based Conditioning	5
Overall Study	NOT COMPLETED	TBI-based Conditioning	9
Overall Study	NOT COMPLETED	nonTBI-based Conditioning	0

Source ClinicalTrials.gov

Adverse events122

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dermatologic (Skin) (COH)	Skin and subcutaneous tissue disorders	Irradiation in Conditioning	2	55	2
other	Dermatologic (Skin) (COH)	Skin and subcutaneous tissue disorders	Carmustine in Conditioning	0	5	0
other	Hepatic	Hepatobiliary disorders	Irradiation in Conditioning	1	55	1
other	Hepatic	Hepatobiliary disorders	Carmustine in Conditioning	0	5	0
other	Mucositis	Gastrointestinal disorders	Irradiation in Conditioning	10	55	10
other	Mucositis	Gastrointestinal disorders	Carmustine in Conditioning	0	5	0
other	Febrile neutropenia	Blood and lymphatic system disorders	Irradiation in Conditioning	7	55	7
other	Febrile neutropenia	Blood and lymphatic system disorders	Carmustine in Conditioning	0	5	0
other	Hemoglobin decreased	Blood and lymphatic system disorders	Irradiation in Conditioning	2	55	2
other	Hemoglobin decreased	Blood and lymphatic system disorders	Carmustine in Conditioning	0	5	0

1 to 10 of 122Source ClinicalTrials.gov

See all 122 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Irradiation in Conditioning
Total, all-cause mortality	Carmustine in Conditioning
Total, other adverse events	Irradiation in Conditioning	39	55
Total, other adverse events	Carmustine in Conditioning	1	5
Total, serious adverse events	Irradiation in Conditioning	0	55
Total, serious adverse events	Carmustine in Conditioning	0	5

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
11707813	BACKGROUND

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA033572	Cancer Center Support Grant	CARPTEN, JOHN D.	BECKMAN RESEARCH INSTITUTE/CITY OF HOPE	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Irradiation in Conditioning vs Carmustine in Conditioning: Short-term and Long-term Treatment-related Toxicities	Trial comparisons
Irradiation in Conditioning vs Carmustine in Conditioning: Progression	Trial comparisons
Irradiation in Conditioning vs Carmustine in Conditioning: Mortality	Trial comparisons
Irradiation in Conditioning vs Carmustine in Conditioning: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00559104

GET https://conductscience.org/api/trials/v1/NCT00559104/events?page=2

API reference For AI assistants